{"organizations": [], "uuid": "2901a99d5c2cc527bf5aa433c6e3e34698a2b3e5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180327.html", "section_title": "Archive News &amp; Video for Tuesday, 27 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-us-fda-says-permitted-marketing-of/brief-u-s-fda-says-permitted-marketing-of-dexcom-g6-integrated-continuous-glucose-monitoring-system-idUSFWN1R90SL", "country": "US", "domain_rank": 408, "title": "BRIEF-U.S. FDA Says Permitted Marketing Of Dexcom G6 Integrated Continuous Glucose Monitoring System", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T04:23:00.000+03:00", "replies_count": 0, "uuid": "2901a99d5c2cc527bf5aa433c6e3e34698a2b3e5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-us-fda-says-permitted-marketing-of/brief-u-s-fda-says-permitted-marketing-of-dexcom-g6-integrated-continuous-glucose-monitoring-system-idUSFWN1R90SL", "ord_in_thread": 0, "title": "BRIEF-U.S. FDA Says Permitted Marketing Of Dexcom G6 Integrated Continuous Glucose Monitoring System", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "fda says permitted marketing of dexcom", "sentiment": "negative"}, {"name": "dexcom inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 27 (Reuters) - Dexcom Inc:\n* U.S. FDA SAYS PERMITTED MARKETING OF THE DEXCOM G6 INTEGRATED CONTINUOUS GLUCOSE MONITORING (ICGM) SYSTEM\n* U.S. FDA SAYS AUTHORIZATION OF ICGM SYSTEM CLASSIFIES THIS NEW TYPE OF DEVICE IN CLASS II & SUBJECTS IT TO CERTAIN CRITERIA CALLED SPECIAL CONTROLS Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-28T04:23:00.000+03:00", "crawled": "2018-03-28T19:08:10.008+03:00", "highlightTitle": ""}